High sensitivity and specificity rates of cobas® HPV test as a primary screening test for cervical intraepithelial lesions in a real-world setting
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0279728 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Laura Alicia Fleider und 6 weiteren Autor:innen. Beteiligte Einrichtung: OBGYN Department, Genital Tract Unit, Hospital de Clínicas "José de San Martín", Buenos Aires University, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Papillomavirus Infections, Uterine Cervical Neoplasms, Carcinoma, Uterine Cervical Dysplasia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche.
Abstract (Originalsprache)
Cervical carcinoma (CC) is the fourth most common malignancy among women. Screening with Papanicolau smear is linked to a reduction in CC incidence rates when screening programs have been developed. However, this technique has several limitations, including moderate sensitivity rates for detection of cervical preneoplastic HPV-related lesions. In this real-world study, we proposed to evaluate the sensitivity and specificity rates of cobas® test, which amplifies target DNA fragments by polymerase chain reaction and hybridization of nucleic acids for the detection of 14 HR-HPV types in a single analysis) used as primary screening test for CC and preneoplastic lesions in women aged 25–65 years in a large University Hospital in Buenos Aires. A total of 1044 patients were included in the sample (median age: 46 years); sensitivity and specificity rates for the HR-HPV test used as primary screening test were 98.66% (95% confidence interval [95CI]: 97.67–99.3%) and 87.15% (95CI: 84.93–89.15%), respectively. The positive predictive value was 88.47% (95CI: 86.54%-90.42%) and the negative predictive value was 98.48% (95CI: 97.75%-99.23%). The cobas® HR-HPV testing was highly sensitive and specific for the detection of CC and preneoplastic lesions in real practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- OBGYN Department, Genital Tract Unit, Hospital de Clínicas "José de San Martín", Buenos Aires University, Buenos Aires, Argentina.
- Molecular Infectious Disease Department, ManLab Laboratories, Buenos Aires, Argentina.
- Gynecological Pathology Division, Pathology Department, Hospital de Clínicas "José de San Martín", Buenos Aires University, Buenos Aires, Argentina.
- Chief of OBGYN Department, Hospital de Clínicas "José de San Martín", Buenos Aires University, Buenos Aires, Argentina.
ORCID-Profile: Laura Alicia Fleider, Facundo Gómez Cherey, María Gabriela García
Förderung
- Roche
Zitieren
APA
Fleider, L. A., de Los Ángeles Tinnirello, M., Gómez Cherey, F., García, M. G., Cardinal, L. H., García Kamermann, F., & Tatti, S. A. (2023). High sensitivity and specificity rates of cobas® HPV test as a primary screening test for cervical intraepithelial lesions in a real-world setting. PLOS ONE. https://doi.org/10.1371/journal.pone.0279728
Vancouver
Fleider LA, de Los Ángeles Tinnirello M, Gómez Cherey F, García MG, Cardinal LH, García Kamermann F, et al. High sensitivity and specificity rates of cobas® HPV test as a primary screening test for cervical intraepithelial lesions in a real-world setting. PLOS ONE. 2023. doi:10.1371/journal.pone.0279728
BibTeX
@article{Fleider2023,
author = {Fleider, Laura Alicia and de Los Ángeles Tinnirello, María and Gómez Cherey, Facundo and García, María Gabriela and Cardinal, Lucía Helena and García Kamermann, Florencia and Tatti, Silvio Alejandro},
title = {High sensitivity and specificity rates of cobas® HPV test as a primary screening test for cervical intraepithelial lesions in a real-world setting},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0279728}
}
EUVIMED